FDA Approves Kisunla For Early Symptomatic Alzheimer's Disease; Phase 3 Study Shows Kisunla Slowed Cognitive And Functional Decline By Up To 35% And Reduced Risk Of Disease Progression By Up To 39%; Once-Monthly Infusions Reduced Amyloid Plaques By...
FDA Approves Kisunla For Early Symptomatic Alzheimer's Disease; Phase 3 Study Shows Kisunla Slowed Cognitive And Functional Decline By Up To 35% And Reduced Risk Of Disease Progression By Up To 39%; Once-Monthly Infusions Reduced Amyloid Plaques By...
FDA批准Kisunla用於早期症狀的阿爾茨海默氏病;第三階段研究表明,Kisunla減緩認知和功能衰退高達35%,並將疾病進展的風險降低高達39%;每月一次的輸注平均減少了84%的澱粉樣斑塊……
FDA Approves Kisunla For Early Symptomatic Alzheimer's Disease; Phase 3 Study Shows Kisunla Slowed Cognitive And Functional Decline By Up To 35% And Reduced Risk Of Disease Progression By Up To 39%; Once-Monthly Infusions Reduced Amyloid Plaques By 84% On Average; Nearly Half Of Participants Completed Treatment In 12 Months
FDA批准Kisunla用於早期症狀的阿爾茨海默氏病;第三階段研究表明,Kisunla減緩認知和功能衰退高達35%,並將疾病進展的風險降低高達39%;每月一次的輸注平均減少了84%的澱粉樣斑塊;近一半的參與者在12個月內完成了治療
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。